NSE filing, NSE: BALAXI. Summary written from the filing by ALFA Finder's alert engine.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹19.15
- Market cap
- ₹105.7 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 43.6×Sector 45.9×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals Limited reported nil activity regarding the re-lodgement of physical share transfer requests for the period ended September 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Balaxi Pharmaceuticals Management Change
Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.
Balaxi Pharmaceuticals Annual General Meeting
Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026. Shareholders voted on financial statements and director re-appointments during the proceedings.
Balaxi Pharmaceuticals Investor Presentation: Key Takeaways
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Other board meeting date announcements
All →Mold-Tek Technologies Board Meeting Date
Mold-Tek Technologies will hold a board meeting on November 4, 2026 to consider unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026. The trading window stays closed until November 6, 2026.
Filtron Engineers Board Meeting Date
Filtron Engineers meets on 04 Nov 2026 to consider unaudited standalone and consolidated quarterly results. Trading window closed from 01 Oct 2026.
Shree Rajasthan Syntex Board Meeting Date
Shree Rajasthan Syntex Ltd has scheduled a board meeting on November 5, 2026, to approve the standalone unaudited financial results for the quarter and half-year.
Richa Info Systems Board Meeting Date
Richa Info Systems rescheduled its board meeting from 30 October to 6 November 2026 due to unavoidable circumstances. Agenda proposes fund raising through preferential or rights issue.
Signatureglobal (India) Board Meeting Date
Signatureglobal (India) has scheduled a board meeting on November 5, 2026, to consider unaudited standalone and consolidated results for Q2 and H1 FY2026-27. The trading window stays closed until November 7, 2026.
Mahasagar Travels Board Meeting Date
Mahasagar Travels will hold a board meeting on 5 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. The trading window opened 1 October 2026.